Pds Biotechnology Corp (PDSB) — 8-K Filings

8-K Filings (42)

• PDS Biotechnology Files 8-K with Exhibits — Apr 15, 2026 Risk: low
  PDS Biotechnology Corporation filed an 8-K on April 15, 2026, reporting other events and financial statements/exhibits. The filing includes an exhibit (EX-99.1)
• 8-K Filing — Mar 30, 2026
• PDS Biotechnology Corp Files 8-K — Dec 9, 2025 Risk: low
  On December 9, 2025, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. It was fil
• 8-K Filing — Dec 2, 2025
• 8-K Filing — Nov 13, 2025
• PDS Biotechnology Corp Files 8-K — Nov 12, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on November 12, 2025, reporting on the entry into a material definitive agreement, results of operations, and other e
• PDS Biotechnology Files 8-K — Nov 10, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on November 10, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeuti
• PDS Biotechnology Files 8-K for Other Events — Oct 29, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on October 29, 2025, to report other events and financial statements. The company, incorporated in Delaware, is based
• PDS Biotechnology Files 8-K — Sep 18, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on September 18, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, is
• PDS Biotechnology Files 8-K — Aug 25, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on August 25, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics
• PDS Biotechnology Corp Files 8-K — Jul 10, 2025 Risk: low
  On July 10, 2025, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
• PDS Biotechnology Files 8-K — Jun 25, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on June 25, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics,
• PDS Biotechnology Corp Files 8-K on Officer/Director Changes — Jun 11, 2025 Risk: medium
  PDS Biotechnology Corporation filed an 8-K on June 11, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of
• PDS Biotechnology Files 8-K — Jun 2, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on June 2, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics, I
• PDS Biotechnology Corp Files 8-K — May 22, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on May 22, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, is based
• PDS Biotechnology Corp Files 8-K — May 8, 2025 Risk: low
  On May 8, 2025, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
• PDS Biotechnology Corp Enters New Agreement, Terminates Old — May 2, 2025 Risk: medium
  On April 30, 2025, PDS Biotechnology Corporation entered into a material definitive agreement and simultaneously terminated a prior agreement. The company also
• PDS Biotechnology Corp. Announces Board Changes — Apr 24, 2025 Risk: medium
  PDS Biotechnology Corporation announced on April 22, 2025, a change in its board of directors. Specifically, the company reported the departure of a director an
• PDS Biotechnology Corp Files 8-K on Financials — Mar 27, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition, as well as financial statements an
• PDS Biotechnology Files 8-K — Mar 13, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on March 13, 2025, reporting on other events and financial statements. The company, formerly known as Edge Therapeuti
• PDS Biotechnology Files 8-K — Mar 7, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on March 7, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics,
• PDS Biotechnology Corp Files 8-K: Material Agreement — Feb 28, 2025 Risk: medium
  On February 26, 2025, PDS Biotechnology Corporation entered into a Material Definitive Agreement. The filing also notes other events and the submission of finan
• PDS Biotechnology Files 8-K for Other Events — Feb 26, 2025 Risk: medium
  PDS Biotechnology Corporation filed an 8-K on February 26, 2025, to report other events and financial statements. The filing indicates a change in the company's
• PDS Biotechnology Corp Files 8-K — Feb 24, 2025 Risk: low
  PDS Biotechnology Corporation filed an 8-K on February 24, 2025, reporting on other events and financial statements/exhibits. The company, formerly Edge Therape
• PDS Biotechnology Corp. Files 8-K Report — Feb 5, 2025 Risk: low
  On February 5, 2025, PDS Biotechnology Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No speci
• PDS Biotechnology Corp Files 8-K on Financials and Operations — Nov 14, 2024 Risk: medium
  PDS Biotechnology Corporation filed an 8-K on November 14, 2024, reporting on Results of Operations and Financial Condition, Other Events, and Financial Stateme
• PDS Biotechnology Files 8-K — Oct 2, 2024 Risk: low
  PDS Biotechnology Corporation filed an 8-K on October 2, 2024, to report on other events and financial statements. The filing does not detail specific new event
• PDS Biotechnology Corp Files 8-K — Sep 16, 2024 Risk: low
  PDS Biotechnology Corporation filed an 8-K on September 16, 2024, to report on various events. The filing includes information related to Regulation FD disclosu
• PDS Biotechnology Corp. Enters and Terminates Agreements — Aug 13, 2024 Risk: medium
  On August 13, 2024, PDS Biotechnology Corp. entered into a material definitive agreement and also terminated a material definitive agreement. The filing does no
• PDS Biotechnology Files 8-K — Aug 8, 2024 Risk: low
  PDS Biotechnology Corporation filed an 8-K on August 8, 2024, to report other events and financial statements. The company, formerly known as Edge Therapeutics,
• PDS Biotechnology Files 8-K Report — Aug 7, 2024 Risk: low
  On August 7, 2024, PDS Biotechnology Corporation filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is
• PDS Biotechnology Corp Files 8-K — Aug 5, 2024 Risk: low
  On August 5, 2024, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• PDS Biotechnology Files 8-K — Aug 1, 2024 Risk: low
  On August 1, 2024, PDS Biotechnology Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
• PDS Biotechnology Files 8-K with Corporate Updates — Jun 24, 2024 Risk: low
  PDS Biotechnology Corporation filed an 8-K on June 24, 2024, reporting on several items including amendments to its articles of incorporation or bylaws, submiss
• PDS Biotechnology to Acquire Itself — Jun 12, 2024 Risk: medium
  PDS Biotechnology Corporation announced on June 12, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of PDS Biotechnology
• PDS Biotechnology Corp Files 8-K on Financials — May 15, 2024 Risk: low
  PDS Biotechnology Corporation filed an 8-K on May 15, 2024, reporting on its financial condition and results of operations. The filing includes financial statem
• PDS Biotechnology Corp Files 8-K — May 10, 2024 Risk: low
  On May 9, 2024, PDS Biotechnology Corporation filed an 8-K report to disclose information regarding "Other Events" and "Financial Statements and Exhibits." The
• PDS Biotechnology Raises $10M in Direct Offering — May 8, 2024 Risk: medium
  PDS Biotechnology Corporation announced on May 8, 2024, that it has entered into a securities purchase agreement to sell approximately $10.0 million of its comm
• PDS Biotechnology Appoints New Director, Reports Officer Compensation — May 2, 2024 Risk: medium
  PDS Biotechnology Corporation announced on May 1, 2024, a change in its Board of Directors, with the appointment of Dr. Alok Sharma as a new director. The compa
• PDS Biotech to Acquire Versant Pharmaceuticals — Mar 27, 2024 Risk: medium
  PDS Biotechnology Corporation announced on March 27, 2024, that it has entered into a definitive agreement to acquire Versant Pharmaceuticals, Inc. The acquisit
• PDS Biotech to Acquire Versant Pharmaceuticals — Mar 13, 2024 Risk: medium
  PDS Biotechnology Corporation announced on March 13, 2024, that it has entered into a definitive agreement to acquire Versant Pharmaceuticals, Inc. The acquisit
• PDS Biotech Reports Leadership/Compensation Changes — Jan 22, 2024
  PDS Biotechnology Corp filed an 8-K on January 22, 2024, to report a "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX